Britain and America have agreed to a major trade agreement that will keep no tariffs on British drug shipments entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these crucial products will be held at zero for a duration of the next three years.
This deal follows recent statements to hike duties on branded drug products, with figures discussed up to double the cost.
"This arrangement with the Britain strengthens the international landscape for cutting-edge drugs and brings long-overdue balance to American-British drug exports," a statement said.
Economic Importance
Pharmaceuticals represent one of the Britain's largest export categories to the America, which is clearly the largest market for major British pharmaceutical firms.
Trade data reveal that in the year to the end of September, the UK exported medicines totaling billions to the US. This amount represented a significant portion of all goods exports in that period.
"This guarantee secures employment, boosts funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Key UK Commitments
The deal includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to double overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Previously, rebates topped 20%.
Industry Background
The deal takes place against a long-running row between the sector and the ministers over drug pricing and regulatory access.
These tensions were heightened by assertions that American customers were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS had to spend more on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the past decade.
